Q2 EPS Estimates for OPKO Health Increased by HC Wainwright

OPKO Health, Inc. (NASDAQ:OPK - Free Report) - Equities research analysts at HC Wainwright lifted their Q2 2025 EPS estimates for OPKO Health in a research note issued to investors on Wednesday, March 12th. HC Wainwright analyst Y. Chen now forecasts that the biotechnology company will post earnings of ($0.07) per share for the quarter, up from their prior estimate of ($0.08). HC Wainwright has a "Buy" rating and a $3.00 price target on the stock. The consensus estimate for OPKO Health's current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for OPKO Health's FY2025 earnings at ($0.30) EPS.

OPKO Health (NASDAQ:OPK - Get Free Report) last issued its earnings results on Thursday, February 27th. The biotechnology company reported $0.01 EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.09. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The company had revenue of $183.60 million for the quarter, compared to the consensus estimate of $155.42 million.

A number of other equities analysts also recently commented on OPK. StockNews.com raised shares of OPKO Health from a "sell" rating to a "hold" rating in a research note on Monday, March 3rd. Barrington Research reissued an "outperform" rating and issued a $2.25 price target on shares of OPKO Health in a research note on Wednesday, March 12th.

Remove Ads

OPKO Health Trading Down 1.9 %

OPK stock traded down $0.04 during trading on Monday, reaching $1.83. 1,855,455 shares of the stock were exchanged, compared to its average volume of 4,529,037. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. The business has a 50 day moving average price of $1.64 and a 200-day moving average price of $1.57. OPKO Health has a 1 year low of $0.87 and a 1 year high of $2.04. The firm has a market capitalization of $1.23 billion, a price-to-earnings ratio of -9.61 and a beta of 1.70.

Institutional Investors Weigh In On OPKO Health

Several large investors have recently added to or reduced their stakes in the business. Wealth Enhancement Advisory Services LLC increased its stake in OPKO Health by 75.3% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company's stock worth $42,000 after buying an additional 12,417 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in OPKO Health by 24.5% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 753,380 shares of the biotechnology company's stock worth $1,107,000 after acquiring an additional 148,322 shares in the last quarter. Two Sigma Advisers LP grew its holdings in OPKO Health by 2.3% during the 4th quarter. Two Sigma Advisers LP now owns 381,197 shares of the biotechnology company's stock worth $560,000 after acquiring an additional 8,396 shares in the last quarter. Two Sigma Investments LP grew its holdings in OPKO Health by 136.1% during the 4th quarter. Two Sigma Investments LP now owns 1,647,567 shares of the biotechnology company's stock worth $2,422,000 after acquiring an additional 949,671 shares in the last quarter. Finally, ProShare Advisors LLC grew its holdings in OPKO Health by 49.0% during the 4th quarter. ProShare Advisors LLC now owns 91,730 shares of the biotechnology company's stock worth $135,000 after acquiring an additional 30,182 shares in the last quarter. 64.63% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other OPKO Health news, CEO Phillip Md Et Al Frost bought 150,000 shares of the business's stock in a transaction that occurred on Friday, January 17th. The shares were purchased at an average cost of $1.47 per share, with a total value of $220,500.00. Following the purchase, the chief executive officer now directly owns 213,186,477 shares in the company, valued at approximately $313,384,121.19. This represents a 0.07 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last three months, insiders have purchased 964,971 shares of company stock valued at $1,493,692. Company insiders own 47.26% of the company's stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.